Drug Type Monoclonal antibody |
Synonyms Anti-alpha5beta1 integrin monoclonal antibody, Anti-α5β1 integrin antibody, Volociximab (USAN) + [4] |
Target |
Action antagonists |
Mechanism α5β1 antagonists(Integrin alpha-5/beta-1 antagonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPhase 2 |
First Approval Date- |
Regulation- |


| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| D06319 | Volociximab | - |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Ovarian Epithelial Carcinoma | Phase 2 | United States | 01 Jul 2007 | |
| Ovarian Epithelial Carcinoma | Phase 2 | Australia | 01 Jul 2007 | |
| Ovarian Epithelial Carcinoma | Phase 2 | Belgium | 01 Jul 2007 | |
| Ovarian Epithelial Carcinoma | Phase 2 | Italy | 01 Jul 2007 | |
| Ovarian Epithelial Carcinoma | Phase 2 | Poland | 01 Jul 2007 | |
| Ovarian Epithelial Carcinoma | Phase 2 | Russia | 01 Jul 2007 | |
| Ovarian Epithelial Carcinoma | Phase 2 | Spain | 01 Jul 2007 | |
| Ovarian Epithelial Carcinoma | Phase 2 | Sweden | 01 Jul 2007 | |
| Ovarian Epithelial Carcinoma | Phase 2 | Switzerland | 01 Jul 2007 | |
| Platinum-Resistant Primary Peritoneal Carcinoma | Phase 2 | United States | 01 Jul 2007 |
Phase 2 | 127 | Volociximab + PLD (q2wk) | epolnjlfoh(iuvwriswvl) = zcqihocssd llykolvmrr (lpvstnuxoj ) | - | 20 May 2009 | ||
Volociximab + PLD (qwk) | epolnjlfoh(iuvwriswvl) = aglxkcncpn llykolvmrr (lpvstnuxoj ) | ||||||
Phase 2 | 19 | Volociximab 15 mg/kg | bvvvntundi(fvizrryhut) = reported in a 56 year-old woman jsciatvaxe (xxonwzxzfq ) View more | Negative | 20 May 2008 | ||
Phase 2 | 40 | jusifmtkaa(venavyolbn) = kywcagsacf frbzjltoum (psbhkwttls ) View more | - | 20 Jun 2007 | |||
Phase 2 | 40 | zhjmbbhbcv(kossnwdqmd) = 1 with arrhythmia (unrelated to M200) qrmnbdgrns (hzhzsscftg ) View more | - | 20 Jun 2006 |






